

# Volasertib (BI6727)

Cat# C3249– 100 mg/ 500 mg/ 1 g

Storage 2 years -20°C Powder | 2 weeks 4°C in DMSO | 6 months -80°C in DMSO

## INTFORMATION

<b>Product Name</b>	Volasertib (BI6727)
<b>Cat NO.</b>	C3249
<b>Size</b>	100 mg/ 500 mg/ 1 g
<b>Description</b>	<p>Like BI2536, BI6727 is an ATP-competitive kinase inhibitor from the dihydropteridinone class of compounds. In addition to Plk1, BI6727 also potently inhibits two closely related kinases Plk2 and Plk3 with IC50 of 5 nM and 56 nM, respectively. BI6727 at concentrations up to 10 <math>\mu</math>M displays no inhibitory activity against a panel of &gt;50 other kinases. BI6727 inhibits the proliferation of multiple cell lines derived from various cancer tissues, including HCT116, NCI-H460, BRO, GRANTA-519, HL-60, THP-1, and Raji cells with EC50 of 23 nM, 21 nM, 11 nM, 15 nM, 32 nM, 36 nM, and 37 nM, respectively. BI6727 treatment (100 nM) in NCI-H460 cells induces an accumulation of mitotic cells with monopolar spindles and positive staining For histone H3 phosphoserine 10, confirming that cells are arrested early in the M phase, followed by induction of apoptosis. Low nanomolar concentrations of BI6727 display potent inhibitory activity against neuroblastoma (NB) tumor-initiating cells (NB TIC) with EC50 of 21 nM, whereas only micromolar concentrations of BI6727 are cytotoxic For normal pediatric neural stem cells. BI6727 induces growth arrest of Daoy and ONS-76 medulloblastoma cells similar to BI 2536. Administration of BI6727 significantly inhibits the growth of multiple human carcinoma xenografts including HCT116, NCI-H460, and taxane-resistant CXB1 colon carcinoma, accompanied by an increase in the mitotic index as well as an increase in apoptosis. In in vivo studies, BI6727 shows better toxicity and pharmacokinetic profile compared to BI2536. For the detailed information of Volasertib(BI6727), the solubility of Volasertib(BI6727) in water, the solubility of Volasertib(BI6727) in DMSO, the solubility of Volasertib(BI6727) in PBS buffer, the animal experiment (test) of Volasertib(BI6727), the cell experiment of Volasertib(BI6727), the in vivo, in vitro and clinical trial test of Volasertib(BI6727), the EC50, IC50,and Affinity of Volasertib(BI6727), Please contact DC Chemicals.</p>
<b>Application</b>	Volasertib(BI6727) is a highly potent PLK1 inhibitor with an IC50 of 0.87 nM; shows 6- and 65-fold greater selectivity against Plk2 and Plk3.
<b>Cas No.</b>	755038-65-4
<b>Purity</b>	> 98%

<b>Solubility</b>	DMSO : 50 mg/mL (80.80 mM; Need ultrasonic) H <sub>2</sub> O : < 0.1 mg/mL (insoluble)
<b>Molecular Formulation</b>	C <sub>34</sub> H <sub>50</sub> N <sub>8</sub> O <sub>3</sub>
<b>Molecular Weight</b>	618.81
<b>Storage</b>	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
<b>Image</b>	

### **PRODUCT USE LIMITATION**

These products are intended for research use only.